-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text . . On October 15th, Gan Li Pharmaceuticals announced that the company intends to manage securities investment with its own idle funds, using a total amount of not more than 1 billion yuan (including invested funds).
within the limits, funds can be recycled. the
announcement shows that the scope of the securities investment management of Ganli Pharmaceuticals is mainly for the purchase of new shares, the subscription of public and non-public offerings of shares of listed companies and equity investments in the proposed listed companies, government bonds, corporate bonds (including convertible bonds), listed securities traded (including H shares), private equity fund investments and other investments permitted by laws and regulations and the rules of the Shanghai Stock Exchange.
announced that this time Gan Li Pharmaceuticals intends to use its own idle funds for securities investment management, aimed at broadening the company's financial investment channels, improve the efficiency of the use of the company's funds, increase financial investment income, for Gan Li Pharmaceuticals and shareholders to create greater benefits.
A-share listing, revenue growth of 25.93 percent is worth mentioning is only on June 5 this year successfully listed in the A-share market, Glycema Pharmaceuticals is mainly engaged in recombinant insulin similars raw materials and injections research and development, production and sales, the main products are insulin preparations, is the first domestic research and development of second- and first-generation third-generation insulin companies, in biosynthetic human insulin and its similars in the development, development and production of domestic and foreign leading positions.
sales of insulin preparations accounted for more than 95% of the total.
addition, Gan Li Pharmaceuticals is known as the "insulin tap" and the so-called "insulin Maotai", with another insulin head company tonghua Dongbao.
that sales and profits have increased for 10 consecutive years since the launch of its related insulin products.
2017-2019, Gan Li Pharmaceutical's operating income increased from 2.37 billion yuan in 2017 to 2.895 billion yuan in 2019, and net profit increased from 1.079 billion yuan in 2017 to 1.167 billion yuan in 2019, according to the company's corporate announcement.
financial report for the first half of 2020 showed that Gan Li Pharmaceuticals' operating income reached 1.207 billion yuan in the first half of the year, up 25.93 percent year-on-year.
insulin holding, research and development investment increased by 105.68% Glycerides pharmaceutical industry's main products are long-acting insulin glycerin, quick-acting insulin, mendon insulin and refined protein zinc recombinant insulin mixed injection (25R) four recombinant insulin-like items, covering long-acting, quick-acting, medium-acting three insulin function market segments.
addition to the sales volume, production and sales rate and average unit price of Ganli Pharmaceuticals' main products, Ganli Pharmaceuticals invested a total of 237.7866 million yuan in research and development projects in the first half of 2020, an increase of 18.03 percent over the same period last year.
, the cost-based research and development investment of 18,734.18 million yuan, an increase of 105.68 percent over the same period last year, accounting for 9.50 percent of sales revenue from 9.50 percent in the same period last year to 15.52 percent in the current period.
Pharmaceutical intelligence data and enterprise announcement inquiries, Gan Li Pharmaceutical is currently in the research project more than 30 items: in the study varieties include a class of 5 new drugs, chemical imitation drugs 6, a class of biological cell therapy technology drugs 3, more than 10 bio-similar drugs.
the development of the project IDF predicts that the number of people with diabetes in China will reach 151 million by 2040.
china's insulin market growth rate also exceeded the global average growth rate.
only clinical drug market, the domestic insulin market in 2019 reached 20 billion yuan.
a number of new products of Gan Li Pharmaceuticals entered the clinical research stage.
further enrich the product line, will become a full product line of insulin manufacturers, better grasp the rapid development of the insulin market market opportunities.
data and content source: Gan Li Pharmaceutical Company Announcement, Pharmaceutical Zhi.com